Daniel Shapiro, Urologic Oncologist at UW Urology, shared a post on X by Pavlos Msaouel, Assistant Professor of Genitourinary Medical Oncology at MD Anderson Cancer Center, about a recent paper by them published in Science Direct.
“Happy to see our editorial European Urology regarding perioperative trials in RCC. Difficult to risk stratify patients in this space accurately to achieve sufficient number of events and power to detect treatment effect.”
Quoting Pavlos Msaouel’s post:
“Commentary European Urology led by Daniel Shapiro on how the observed adjuvant immunotherapy trial result discrepancies in kidney cancer can be explained by simple trial design principles.”
Authors: Daniel Shapiro, Pavlos Msaoul
More posts featuring Daniel Shapiro.
